NCT00907036View on ClinicalTrials.gov

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

PHASE2UnknownINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2015

Conditions

Lymphoma

Interventions

BIOLOGICAL

alemtuzumab

BIOLOGICAL

donor lymphocytes

DRUG

cyclosporine

DRUG

fludarabine phosphate

DRUG

melphalan

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Sponsors

Lead Sponsor

Cancer Research UK

All Listed Sponsors

lead

Cancer Research UK

OTHER